TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Normal general cognitive function~* High Risk Group Only: Family history (1st degree relative) of AD~* Low Risk Group Only: No family history (1st or 2nd degree relative) of AD~* Visual and auditory acuity adequate for neuropsychological testing~Exclusion Criteria:~* Current or past history of~* neurological illnesses/conditions~* head trauma with significant loss of consciousness~* medical illnesses/conditions that may affect brain function~* severe psychiatric disorder~* substance abuse~* unstable or severe cardiovascular disease or asthmatic condition~* history of stroke or transient ischemic attack

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Donepezil HCL (Type: ACTIVE_COMPARATOR): Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo for 24 weeks.
- Control Group (Type: NO_INTERVENTION): Participants without a family history of AD will undergo the study evaluations but will not receive any study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor \> 1.0 cm), II or III disease.~2. Measurable disease by physical examinations or diagnostic breast imaging (mammography, ultrasonography or MR).~3. Pre-treatment core or incisional biopsy. Patients may not have had definitive primary surgery.~4. Male or female, 18 years of age or older.~5. ECOG performance status 0 or 1.~6. Adequate organ function as defined in the protocol.~Exclusion Criteria:~1. Prior radiation therapy, cytotoxic therapy or systemic therapy for breast cancer. Prior use of tamoxifen or raloxifene as chemoprevention is allowed but must be discontinued prior to study entry.~2. Metastatic (Stage IV) breast cancer~3. Patients who have had only a pre-treatment fine needle aspiration (FNA) are excluded.~4. Current therapeutic treatment on another clinical trial with an investigational agent.~5. Any of the following within the 6 months prior to starting study treatment: -myocardial infarction -severe/unstable angina -coronary/peripheral artery bypass graft -congestive heart failure -cerebrovascular accident including transient ischemic attack -pulmonary embolus~6. Ongoing cardiac dysrhythmias of NCI CTCAE grade \>=2, atrial fibrillation of any grade, or QTc interval \>450 msec for males or \>470 msec for females.~7. Hypertension that cannot be controlled by medications.~8. Current treatment with therapeutic doses of any anti-coagulant. Prophylactic use of anticoagulants is allowed.~9. Known human immunodeficiency virus (HIV) infection.~10. Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test prior to first day of study medication.~11. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): The study will be conducted in 3 sequential treatment segments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yeego! Healthy Eating & Gardening School-Based Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elementary schools in Tsaile and Shiprock will have been in existence for at least three years, school size (have between 40 to 100 students in grades 3 and 4 combined), have more than two-thirds Navajo students and satisfy a garden site checklist that can overcome garden barriers (e.g. have access to water)~* Assessment is restricted to Male/female students in grades 3 and 4 attending school in either Tsaile or Shiprock~Exclusion criteria:~* Students in grades other than 3rd or 4th are not eligible for assessment

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Intervention schools receive a raised bed school garden and a curriculum of healthy eating and gardening lessons.~3rd and 4th grade students in the intervention group received the curriculum and exposure to the school garden during the academic school year (2019-20)~Behavioral Gardening Exposure: Assistance provided with planting and maintaining the school garden~Healthy Eating and Gardening Curriculum: 14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season.
- Comparison Group (Type: NO_INTERVENTION): For the comparison group schools, no program was provided in school year (2019-2020).~After the trial, and the follow-up evaluation, in school year 2020-2021 comparison schools received delayed intervention components as follows: School gardens were created during the 2020-2021 school year (subject to delays due to pandemic restrictions). Curriculum materials were supplied to the school for use by teachers as they saw fit, after pandemic restrictions were lifted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. aged 18 to 65 years old (including 18 and 65 years);~2. male and non-pregnant female;~3. respiratory tract specimens or hematology samples detected positive results of SARS-CoV-2 by real-time transcriptase polymerase chain reaction (RT-PCR).~4. mild clinical status, defined as having mild clinical symptoms but no signs of pneumonia on imaging or moderate clinical status, defined as having fever, respiratory symptoms and pneumonia on imaging or severe clinical status, defined as having an oxygen saturation (SaO2) of 93% or less at ambient air or a ratio of the partial pressure of oxygen (PaO2) to the fraction of inspired oxygen (FiO2) at or below 400 mgHg, which can be rectified by oxygen inhalation through nasal catheter or face mask.~Exclusion Criteria:~included a physician decision that involvement in the trial was not in the patient's best interest, known allergic reaction and / or severe allergic to arbidol, blood system dysfunction (platelet count \<100×109/L, hemoglobin level \<90g/L), severe liver dysfunction (total bilirubin level \>2 times the normal upper limit, aspartic aminotransferase and alanine aminotransferase levels \>3 times normal upper limit),severe renal dysfunction (serum creatinine \>1.5 times the upper limit of normal value, calculated creatinine clearance rate \<50 ml/min), treated with arbidol before admission, history of severe heart disease or clinically significant arrhythmia considered unsafe for the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arbidol tablets + basic treatment (Type: EXPERIMENTAL): None
- basic treatment (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris);~* Have plaque-type psoriasis covering at least 10% of total body surface area~* Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis~Exclusion Criteria:~* Non-plaque or drug induced forms of psoriasis~* Cannot discontinue current systemic and/or topical therapies for the treatment of psoriasis~* Cannot discontinue phototherapy~* Any uncontrolled significant medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP 690,550 5 mg BID+Placebo BIW (Type: EXPERIMENTAL): None
- CP 690,550 10 mg BID+Placebo BIW (Type: EXPERIMENTAL): None
- Placebo BID+Etanercept 50 mg BIW (Type: ACTIVE_COMPARATOR): None
- Placebo BID+Placebo BIW (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have Type II diabetes mellitus (non-insulin-dependent).~* Females must be post-menopausal (\> 12 months without a menstrual period), surgically sterile, or must be using oral contraceptive, Norplant, Depo-provera, an IUD, or a diaphragm with spermicide or condoms. Females of childbearing potential must use acceptable contraceptive measures for at least one month prior to screening and for 30 days after completing the study.~* Must have been on insulin therapy alone continuously for at least 8 weeks prior to screening (minimum dose of 30 units per day). Patients taking insulin in combination with a single oral antidiabetic agent may have their oral agent discontinued and their insulin dose optimized over an 8 week period prior to screening if they are considered good study candidates in all other respects.~* HbA1c \> 7.5% at Pre-screen or at Screen for subjects who discontinue their antidiabetic agent at pre-screening.~* Provide signed Informed Consent.~Exclusion Criteria:~* Females who are lactating, pregnant, or planning to become pregnant.~* Use of any drug called a thiazolidinedione within 6 months prior to screening, or more than one oral antidiabetic agent (including combinations of agents such as Glucovance) in combination with insulin in the 3 months prior to screening.~* Use of any investigational drug for blood glucose control within 3 months of screening regardless of the treatment regimen, or use of any other investigational agent within 30 days preceding study entry.~* Use of niacin (not including doses found in multivitamins) or oral corticosteroids within 3 months of screening.~* Patients with ongoing swelling due to fluid accumulation or history of such requiring treatment with a drug in the 12 months prior to screening.~* Patients with a documented history of significant hypersensitivity (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to the drugs called thiazolidinediones or similar drugs, or with prior fluid related intolerability to thiazolidinediones.~* Presence of clinically significant kidney or liver disease.~* Anemia.~* Presence of unstable or severe angina or coronary insufficiency.~* Patients with ongoing CHF (chronic heart failure) or history of CHF.~* Recent history or suspicion of current drug abuse or alcohol abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of pancreatic adenocarcinoma~* Stage III or IV disease~* Age \> 17 \< 76 years~* Karnofsky Performance Status \> 50~* Measurable disease (only for phase II part)~* Adequate bone marrow (GB \> 3500/mm3, neutrophils \> 1500/mm3; platelets \> 100000/mm3; hemoglobin \> 10 g/dl), liver (total bilirubin \< 2 mg/dL; SGOT e SGPT \< 3 UNL) and kidney function (serum creatinin \< 1.5 mg/dL;)~* Written informed consent~Exclusion Criteria:~* previous chemotherapy~* concurrent treatment with other experimental drugs~* previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasms without evidence of disease at least from 5 years~* symptomatic brain metastases~* history of interstitial lung disease~* presence of serious disease which can compromise safety (cardiac failure, previous myocardial infarction within the prior 6 months, cardiac arrhythmia, history of psychiatric disabilities)~* pregnancy and lactating~* History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PAXG regimen (Type: EXPERIMENTAL): cisplatin at 30 mg/m2 on days 1 and 15, nab-paclitaxel at the RP2D on days 1 and 15, capecitabine at 1250 mg/ m2 days 1-28, gemcitabine at 800 mg/ m2 on days 1 and 15 every 4 weeks
- gemcitabine + nab-paclitaxel (Type: ACTIVE_COMPARATOR): gemcitabine at 1000 mg/ m2 on days 1, 8 and 15 every 4 weeks + nab-paclitaxel at 125 mg/ m2 on days 1, 8 and 15 every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient's seated systolic BP (SeSBP) will be greater than or equal to 95th percentile for gender and height-for- age, or greater than or equal to 90th percentile if the patient is diabetic, or has glomerular kidney disease, or has a family history of hypertension.~* Negative for hepatitis B and C~* Negative for HIV~Exclusion Criteria:~* Patient should not have serious other conditions that could interfere with the analysis of the results or that could interfere with the well-being of the patient in the trial.~* Known sensitivity to olmesartan medoxomil~* Taking prohibited medication~* Consumed greater than 180 mg of caffeine daily~* Malignant hypertension~* History of congestive heart failure, cardiomyopathy, or obstructive valve disease~* Renal transplant within the previous 6 months~* Severe nephritic syndrome not in remission

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Period 2 (Type: EXPERIMENTAL): For Cohorts A and B, olmesartan medoxomil suspension 2.5 mg to 40 mg in patients 6-16 years old, depending on weight.~For Cohort C, olmesartan medoxomil suspension 0.3 mg/kg to in patients 1-5 years old.
- Period 3 (Type: EXPERIMENTAL): Cohorts A, B, C - olmesartan medoxomil suspension or placebo taken once daily. Olmesartan medoxomil dose continued as in previous period.
- Period 4 (Type: EXPERIMENTAL): Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Diabetes Data Management System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Health Care Professionals:~  1. Must have experience using diabetes data management software in the medical office such as downloading meters, reviewing reports (computer screen or printouts), or assisting in patients' diabetes disease management using software.~ 2. May include: endocrinologists, primary care physicians, nurse educators, or other medical staff involved in downloading meters or interpreting the data output.~* Lay users must:~  1. Be at least 18 years of age.~ 2. Have diabetes (or be the parent or legal guardian of a child with diabetes) and have been testing blood sugar at home at least twice daily for one month or more.~ 3. Be able to speak, read and understand English.~ 4. Currently using diabetes management software at home or be familiar with diabetes management software. At least 75% of subjects must have been using software for at least one month.~ 5. Have experience using PC programs or browsing the internet.~Exclusion Criteria:~* Persons working for a competitive medical device company.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- health care professionals and lay users (Type: None): h= 8 health care professionals p= 43 lay users

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* the presence of Rome III criteria for IBS ;~* Patients scheduled for colonoscopy examination or having negative screening examinations~* Aged between 18 and 65 years old~Exclusion Criteria:~* Antibiotic, probiotic or laxative usage within 4 weeks.~* organic gastrointestinal diseases~* Severe systematic disease: diabetes mellitus, hepatic, renal or cardiac dysfunction, thyroid disease or tumor etc.~* pregnancy or lactation.~* previous major or complicated abdominal surgery.~* severe endometriosis and dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- laxative-probiotic sequential (Type: EXPERIMENTAL): laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks，immediately after colonoscopy
- probiotic (Type: ACTIVE_COMPARATOR): Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks.
- Laxative followed by Probiotic 2 weeks later (Type: ACTIVE_COMPARATOR): laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the last 2 weeks with two weeks interval after colonoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra Articular Injection of Microfat and PRP in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 20 to 65 years of age~* Symptomatic knee osteoarthritis , ICRS grade 2, 3 ou 4 with VAS \> 4 and failure of medical treatment for at least one year~* BMI between 20 to 30~* Written informed consent, signed by patient or legal representative~* HB \> 10g/dl~* Negative pregnancy test~* Social security affiliated~Exclusion Criteria:~* IRM contre-indications: ocular loose bodies, pace maker, neurostimulateur, cochlear implant, vascular clips, mettalic cardiac valve~* BMI \< 20~* Thrombocytopenia \< 150 G/L~* Thrombocytosis \> 450 G/L~* Thrombopathy~* TP \< 70%~* TCA patient / witness rapport \> 1,20~* Anaemia: HB \< 10g/dl~* Positive serology VIH1 and 2, Agp24, Ac HCV, Ag HbS, AcHbc, Ac HTLV I and II, TPHA~* Treatment by platelet inhibiting agent, aspirin, anti vitamin K completed more than 2 weeks before inclusion~* Chronic treatment by corticosteroid per os or treatment completed more than 2 weeks before inclusion~* Intra articular knee injection of corticosteroid more than 8 weeks before inclusion~* Intra articular knee injection of hyaluronic acid more than 8 weeks before inclusion~* NSAI treatment completed more than 2 weeks before inclusion~* Fever or recent disease~* Auto immune disease~* Inflammatory Arthritis~* Immune deficit~* Infectious disease~* Malignant tumor being treated or history of malignant tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Microfat + PRP 3M platelets (Type: EXPERIMENTAL): microfat (5 ml) associated with PRP with a dose of 3 billions of platelets (5 ml)
- Microfat + PRP 1M platelets (Type: EXPERIMENTAL): microfat (5 ml) associated with PRP with a dose of 1 billion of platelets (5 ml)
- Microfat (Type: EXPERIMENTAL): microfat (5 ml) and saline solution (5 ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete